TENAYA THERAPEUTICS INC. - COMMON STOCK

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

26 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

09 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

05 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

02 10 2023 17:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

21 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

31 8 2023 16:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

09 8 2023 16:05:01 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference

02 8 2023 16:05:02 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

10 5 2023 16:19:57 提供 Nasdaq GlobeNewswire

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting

03 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

02 5 2023 07:50:18 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

21 4 2023 16:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

08 3 2023 16:01:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

07 2 2023 17:17:05 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

09 1 2023 07:00:02 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

07 12 2022 16:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

28 11 2022 08:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

23 11 2022 09:00:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Closing of Public Offering

21 11 2022 17:45:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Pricing of Public Offering

17 11 2022 00:39:47 提供 Nasdaq GlobeNewswire